322 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author임태연-
dc.date.accessioned2017-12-05T04:57:00Z-
dc.date.available2017-12-05T04:57:00Z-
dc.date.issued2016-02-
dc.identifier.citationEXPERT OPINION ON DRUG DELIVERY, v. 13, NO 5, Page. 709-723en_US
dc.identifier.issn1742-5247-
dc.identifier.issn1744-7593-
dc.identifier.urihttp://www.tandfonline.com/doi/full/10.1517/17425247.2016.1144588-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/33949-
dc.description.abstractIntroduction: Ischemic stroke is caused by reduced blood supply and leads to loss of brain function. The reduced oxygen and nutrient supply stimulates various physiological responses, including induction of growth factors. Growth factors prevent neuronal cell death, promote neovascularization, and induce cell growth. However, the concentration of growth factors is not sufficient to recover brain function after the ischemic damage, suggesting that delivery of growth factors into the ischemic brain may be a useful treatment for ischemic stroke.Areas covered: In this review, various approaches for the delivery of growth factors to ischemic brain tissue are discussed, including local and targeting delivery systems.Expert opinion: To develop growth factor therapy for ischemic stroke, important considerations should be taken into account. First, growth factors may have possible side effects. Thus, concentration of growth factors should be restricted to the ischemic tissues by local administration or targeted delivery. Second, the duration of growth factor therapy should be optimized. Growth factor proteins may be degraded too fast to have a high enough therapeutic effect. Therefore, delivery systems for controlled release or gene delivery may be useful. Third, the delivery systems to the brain should be optimized according to the delivery route.en_US
dc.description.sponsorshipThis work was supported by a grant from the National Research Foundation of Korea, funded by the Ministry of Science, ICT and Future Planning (NRF-2013R1A1A2059236). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.en_US
dc.language.isoenen_US
dc.publisherTAYLOR & FRANCIS LTDen_US
dc.subjectdeliveryen_US
dc.subjectgrowth factorsen_US
dc.subjectischemic brainen_US
dc.subjecttargetingen_US
dc.subjectstrokeen_US
dc.titleTargeted delivery of growth factors in ischemic stroke animal modelsen_US
dc.typeArticleen_US
dc.relation.no5-
dc.relation.volume13-
dc.identifier.doi10.1517/17425247.2016.1144588-
dc.relation.page709-723-
dc.relation.journalEXPERT OPINION ON DRUG DELIVERY-
dc.contributor.googleauthorRhim, Taiyoun-
dc.contributor.googleauthorLee, Minhyung-
dc.relation.code2016006198-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF ENGINEERING[S]-
dc.sector.departmentDEPARTMENT OF BIOENGINEERING-
dc.identifier.pidrhim-
Appears in Collections:
COLLEGE OF ENGINEERING[S](공과대학) > BIOENGINEERING(생명공학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE